Amyloid-β Impairs Synaptic Inhibition via GABA(A) Receptor Endocytosis.
TL;DR: It is concluded that Aβ weakens synaptic inhibition via downregulation of GABAA receptors through degradation of excitatory synaptic transmission associated with impaired synaptic plasticity.
read more
Abstract: Amyloid β (Aβ) is thought to play an important role in the pathogenesis of Alzheimer's disease. Aβ may exert its neurotoxic effects via multiple mechanisms and in particular through degradation of excitatory synaptic transmission associated with impaired synaptic plasticity. In contrast, much less is known about Aβ effects at inhibitory synapses. This study investigates the impact of acute Aβ1-42 application on GABAergic synaptic transmission in rat somatosensory cortex in vitro. Whole-cell voltage-clamp recordings were obtained from layer V pyramidal cells, and monosynaptic GABA(A) receptor-mediated IPSCs were elicited. Bath-applied Aβ (1 μm) depressed the IPSCs on average to 60% of control, whereas a reversed sequence control peptide was ineffective. Paired-pulse stimuli indicated a postsynaptic site of action. This was further corroborated by a decreased postsynaptic responsiveness to local puffs of the GABAA receptor agonist isoguvacine. The Aβ-induced IPSC decline could be prevented with intracellular applications of p4, a blocker of GABA(A) receptor internalization. It is concluded that Aβ weakens synaptic inhibition via downregulation of GABA(A) receptors.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?
Bryce A. Mander,Joseph R. Winer,William J. Jagust,William J. Jagust,Matthew P. Walker,Matthew P. Walker +5 more
TL;DR: A role for NREM sleep disruption as a novel factor linking cortical Aβ to impaired hippocampus-dependent memory consolidation and the possibility of sleep as a new treatment target in aging, affording preventative and therapeutic benefits is evaluated.
405
Therapeutics of Neurotransmitters in Alzheimer’s Disease
TL;DR: The purpose of the article is to assess the latest developments in neurotransmitters research using cell and mouse models of AD, and updated the current status of clinical trials using neurotransmitter' agonists/antagonists in AD.
229
Diabetes and Alzheimer's disease crosstalk.
TL;DR: Novel findings in animal model and clinical studies involving the use of anti-diabetic compounds as promising therapeutics for AD are discussed, highlighting the involvement of several novels pathological molecular mechanisms induced by diabetes that increase AD pathogenesis.
224
A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain.
Shaomin Li,Dennis J. Selkoe +1 more
TL;DR: A mechanistic hypothesis for synaptic failure in Alzheimer's disease that can be modified as new knowledge is added and specific therapeutics are developed is synthesized.
215
Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice
TL;DR: It is suggested that fisetin has a potent neuroprotective effect against Aβ1–42-induced neurotoxicity and demonstrated that polyphenolic flavonoids such as f isetin could be a beneficial, effective and safe neuroProtective agent for preventing neurological disorders such as AD.
190
References
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj Linda B. Selenica,Milene Brownlow,Jeffy Jimenez,Daniel C. Lee,Gabriela Pena,Chad A. Dickey,Marcia N. Gordon,Dave Morgan +7 more
TL;DR: The data suggest that even brief elevations in Aβ production, may have enduring impact on the risk for tauopathy, and Soluble Aβ1-42 oligomers have long-lasting effects on tau phosphorylation in the rTg4510 model.
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.
Dominic M. Walsh,Igor Klyubin,Julia V. Fadeeva,William K. Cullen,Roger Anwyl,Michael S. Wolfe,Michael J. Rowan,Dennis J. Selkoe +7 more
TL;DR: It is reported that natural oligomers of human Aβ are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell, indicating that synaptotoxic Aβ oligomers can be targeted therapeutically.
4.6K
Alzheimer's Disease Is a Synaptic Failure
TL;DR: Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid β protein.
4.4K
APP processing and synaptic function.
Flavio Kamenetz,Taisuke Tomita,Helen Hsieh,Helen Hsieh,Guy R. Seabrook,David R. Borchelt,Takeshi Iwatsubo,Sangram S. Sisodia,Roberto Malinow,Roberto Malinow +9 more
TL;DR: It is shown that neuronal activity modulates the formation and secretion of Abeta peptides in hippocampal slice neurons that overexpress APP, and it is proposed that activity-dependent modulation of endogenous Abeta production may normally participate in a negative feedback that could keep neuronal hyperactivity in check.
1.6K
Amyloid-[beta]-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Jorge J. Palop,Lennart Mucke +1 more
TL;DR: Recent evidence that Aβ may be part of a mechanism controlling synaptic activity, acting as a positive regulator presynaptically and a negative regulator postsynaptically is discussed.